Legend Biotech Corp

LEGN

17.100USD

+0.400+2.40%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

Legend Biotech Corp's Score

Industry at a Glance

Industry Ranking

74 / 392

Overall Ranking

195 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Legend Biotech Corp Highlights

StrengthsRisks

Legend Biotech Corporation is a global biopharmaceutical company. The Company is engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 436.08% year-on-year.

Overvalued

The company’s latest PE is -13.16, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 88.44M shares, decreasing 19.19% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 4.98K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.18.

Analyst Rating

Based on 19 analysts

Buy

Current Rating

64.508

Target Price

+287.44%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Legend Biotech Corp is 8.14, ranking 59 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 272.33M, representing a year-over-year increase of 69.99%, while its net profit experienced a year-over-year increase of 68.33%.

Score

Industry at a Glance

Previous score

8.14

Change

0



Financials

6.66

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.37

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.66

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Legend Biotech Corp is 7.24, ranking 145 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -13.16, which is -2.63% below the recent high of -12.82 and -211.52% above the recent low of -41.01.

Score

Industry at a Glance

Previous score

7.24

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 74/392

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Legend Biotech Corp is 8.32, ranking 135 out of 392 in the Biotechnology & Medical Research industry. The average price target is 74.00, with a high of 91.00 and a low of 48.00.

Score

Industry at a Glance

Previous score

8.32

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Legend Biotech Corp is 6.46, ranking 241 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 22.07 and the support level at 14.19, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.38

Change

0.08

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Legend Biotech Corp is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 47.89%, representing a quarter-over-quarter increase of 0.25%. The largest institutional shareholder is Matthews International Capital Management, holding a total of 956.82K shares, representing 0.52% of shares outstanding, with 13.35% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

25.20M

+8.97%

HHLR Advisors, Ltd.

6.30M

+1.54%

Westfield Capital Management Company, L.P.

6.09M

-5.84%

Suvretta Capital Management, LLC

3.82M

+1.17%

BlackRock Institutional Trust Company, N.A.

3.04M

+6.60%

Deerfield Management Company, L.P.

2.96M

--

Artisan Partners Limited Partnership

2.55M

+20.06%

Genscript Biotech Corp

2.25M

--

Fidelity Institutional Asset Management

2.50M

-1.63%

Janus Henderson Investors

2.13M

+1.55%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Legend Biotech Corp is 5.94, ranking 33 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.10. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Legend Biotech Corp’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

Legend Biotech Corp

LEGN

6.97 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.53 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ionis Pharmaceuticals Inc

IONS

8.38 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.37 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.17 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment